Literature DB >> 26159872

Clinical utility of dual-energy contrast-enhanced spectral mammography for breast microcalcifications without associated mass: a preliminary analysis.

Yun-Chung Cheung1,2, Hsiu-Pei Tsai3,4, Yung-Feng Lo3,4, Shir-Hwa Ueng5, Pei-Chin Huang6, Shin-Chih Chen3,4.   

Abstract

OBJECTIVE: To assess the utility of dual-energy contrast-enhanced spectral mammography (DE-CESM) for evaluation of suspicious malignant microcalcifications.
METHODS: Two hundred and fifty-six DE-CESMs were reviewed from 2012-2013, 59 cases fulfilled the following criteria and were enrolled for analysis: (1) suspicious malignant microcalcifications (BI-RADS 4) on mammogram, (2) no related mass, (3) with pathological diagnoses. The microcalcification morphology and associated enhancement were reviewed to analyse the accuracy of the diagnosis and cancer size measurements versus the results of pathology.
RESULTS: Of the 59 microcalcifications, 22 were diagnosed as cancers, 19 were atypical lesions and 18 were benign lesions. Twenty (76.9 %) cancers, three (11.55 %) atypia and three (11.55 %) benign lesions revealed enhancement. The true-positive rate of intermediate- and high-concern microcalcifications was significantly higher than that of low-concern lesions (93.75 % vs. 50 %). Overall, the diagnostic sensitivity of enhancement was 90.9 %, with 83.78 % specificity, 76.92 % positive predictive value, 93.94 % negative predictive value and 86.4 % accuracy. Performance was good (AUC = 0.87) according to a ROC curve and cancer size correlation with a mean difference of 0.05 cm on a Bland-Altman plot.
CONCLUSIONS: DE-CESM provides additional enhancement information for diagnosing breast microcalcifications and measuring cancer sizes with high correlation to surgicohistology. KEY POINTS: • DE-CESM provides additional enhancement information for diagnosing suspicious breast microcalcifications. • The enhanced cancer size closely correlates to microscopy by Bland-Altman plot. • DE-CESM could be considered for evaluation of suspicious malignant microcalcifications.

Entities:  

Keywords:  Breast cancer; Breast microcalcification; Dual-energy Contrast-enhanced Spectral Mammography; Mammography; Surgical planning

Mesh:

Substances:

Year:  2015        PMID: 26159872     DOI: 10.1007/s00330-015-3904-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  25 in total

Review 1.  Rationale for a trial of screening breast ultrasound: American College of Radiology Imaging Network (ACRIN) 6666.

Authors:  Wendie A Berg
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

2.  Two-view and single-view tomosynthesis versus full-field digital mammography: high-resolution X-ray imaging observer study.

Authors:  Matthew G Wallis; Elin Moa; Federica Zanca; Karin Leifland; Mats Danielsson
Journal:  Radiology       Date:  2012-01-24       Impact factor: 11.105

Review 3.  Applications and literature review of the BI-RADS classification.

Authors:  S Obenauer; K P Hermann; E Grabbe
Journal:  Eur Radiol       Date:  2005-01-26       Impact factor: 5.315

4.  A comparison of the accuracy of film-screen mammography, full-field digital mammography, and digital breast tomosynthesis.

Authors:  M J Michell; A Iqbal; R K Wasan; D R Evans; C Peacock; C P Lawinski; A Douiri; R Wilson; P Whelehan
Journal:  Clin Radiol       Date:  2012-05-23       Impact factor: 2.350

5.  BI-RADS categorization as a predictor of malignancy.

Authors:  S G Orel; N Kay; C Reynolds; D C Sullivan
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

6.  Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial.

Authors:  Massimo Bazzocchi; Chiara Zuiani; Pietro Panizza; Chiara Del Frate; Franca Soldano; Miriam Isola; Francesco Sardanelli; Gian Marco Giuseppetti; Giovanni Simonetti; Vincenzo Lattanzio; Alessandro Del Maschio
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

7.  MRI of occult breast carcinoma in a high-risk population.

Authors:  Elizabeth A Morris; Laura Liberman; Douglas J Ballon; Mark Robson; Andrea F Abramson; Alexandra Heerdt; D David Dershaw
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

8.  Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study.

Authors:  Ute Kettritz; Kerstin Rotter; Ingrid Schreer; Margarete Murauer; Rüdiger Schulz-Wendtland; Daniela Peter; Sylvia H Heywang-Köbrunner
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

9.  The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories.

Authors:  L Liberman; A F Abramson; F B Squires; J R Glassman; E A Morris; D D Dershaw
Journal:  AJR Am J Roentgenol       Date:  1998-07       Impact factor: 3.959

Review 10.  MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature.

Authors:  Ritse M Mann; Yvonne L Hoogeveen; Johan G Blickman; Carla Boetes
Journal:  Breast Cancer Res Treat       Date:  2007-02-15       Impact factor: 4.872

View more
  22 in total

1.  Classification of contrast-enhanced spectral mammography (CESM) images.

Authors:  Shaked Perek; Nahum Kiryati; Gali Zimmerman-Moreno; Miri Sklair-Levy; Eli Konen; Arnaldo Mayer
Journal:  Int J Comput Assist Radiol Surg       Date:  2018-10-26       Impact factor: 2.924

2.  Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation.

Authors:  Eva M Fallenberg; Florian F Schmitzberger; Heba Amer; Barbara Ingold-Heppner; Corinne Balleyguier; Felix Diekmann; Florian Engelken; Ritse M Mann; Diane M Renz; Ulrich Bick; Bernd Hamm; Clarisse Dromain
Journal:  Eur Radiol       Date:  2016-11-28       Impact factor: 5.315

3.  Dual-energy contrast-enhanced spectral mammography (CESM) for breast cancer screening.

Authors:  Vera Sorin; Miri Sklair-Levy
Journal:  Quant Imaging Med Surg       Date:  2019-11

4.  The emerging role of contrast-enhanced mammography.

Authors:  Andrea Cozzi; Simone Schiaffino; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2019-12

5.  Diagnostic performance of contrast-enhanced dual-energy spectral mammography (CESM): a retrospective study involving 644 breast lesions.

Authors:  María Del Mar Travieso-Aja; Daniel Maldonado-Saluzzi; Pedro Naranjo-Santana; Claudia Fernández-Ruiz; Wilsa Severino-Rondón; Mario Rodríguez Rodríguez; Víctor Vega Benítez; Octavio Pérez-Luzardo
Journal:  Radiol Med       Date:  2019-06-27       Impact factor: 3.469

6.  Contrast-enhanced mammography for the assessment of screening recalls: a two-centre study.

Authors:  Andrea Cozzi; Simone Schiaffino; Marianna Fanizza; Veronica Magni; Laura Menicagli; Cristian Giuseppe Monaco; Adrienn Benedek; Diana Spinelli; Giovanni Di Leo; Giuseppe Di Giulio; Francesco Sardanelli
Journal:  Eur Radiol       Date:  2022-06-01       Impact factor: 7.034

7.  Quantitative analysis of enhanced malignant and benign lesions on contrast-enhanced spectral mammography.

Authors:  Chih-Ying Deng; Yu-Hsiang Juan; Yun-Chung Cheung; Yu-Ching Lin; Yung-Feng Lo; GiGin Lin; Shin-Cheh Chen; Shu-Hang Ng
Journal:  Br J Radiol       Date:  2018-02-27       Impact factor: 3.039

8.  Differentiation of ductal carcinoma in-situ from benign micro-calcifications by dedicated breast computed tomography.

Authors:  Shadi Aminololama-Shakeri; Craig K Abbey; Peymon Gazi; Nicolas D Prionas; Anita Nosratieh; Chin-Shang Li; John M Boone; Karen K Lindfors
Journal:  Eur J Radiol       Date:  2015-10-01       Impact factor: 3.528

Review 9.  Contrast-enhanced mammography: past, present, and future.

Authors:  Julie Sogani; Victoria L Mango; Delia Keating; Janice S Sung; Maxine S Jochelson
Journal:  Clin Imaging       Date:  2020-09-19       Impact factor: 1.605

10.  Contrast-Enhanced Spectral Mammography: Importance of the Assessment of Breast Tumor Size.

Authors:  Luca Nicosia; Anna Carla Bozzini; Antuono Latronico; Enrico Cassano
Journal:  Korean J Radiol       Date:  2020-09-10       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.